• Fifty 1 Labs outlined plans for a U.S.-focused telehealth platform for peptide services, separate from its investigational clinical-development programs.
• The model targets digital intake, clinician evaluation, prescription routing to compounding pharmacies, monitoring coordination, and subscription-based patient support.
• Revenue is expected from monthly memberships, virtual visits, care-management services, lab and monitoring coordination, and pharmacy-related service arrangements where permitted.
• Launch timing remains contingent on regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fifty 1 Labs Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608070900ACCESSWRNAPR_____1204390) on August 07, 2026, and is solely responsible for the information contained therein.